Edison Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 2005-01-01
- Employees
- 11
- Market Cap
- -
Safety and Biomarker Study of PTC-589 in Participants With Parkinson's Disease
Phase 2
Completed
- Conditions
- Parkinson's Disease
- Interventions
- Drug: PTC-589
- First Posted Date
- 2015-06-04
- Last Posted Date
- 2022-05-03
- Lead Sponsor
- Edison Pharmaceuticals Inc
- Target Recruit Count
- 44
- Registration Number
- NCT02462603
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇩🇪DZNE Site, Tuebingen, Germany
🇺🇸University of California, San Francisco, San Francisco, California, United States
Analysis of the Glutathione Cycle in Children With Rett Syndrome
Withdrawn
- Conditions
- Rett Syndrome
- First Posted Date
- 2015-02-10
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Edison Pharmaceuticals Inc
- Registration Number
- NCT02360436
- Locations
- 🇺🇸
University of Alabama, Birmingham, Birmingham, Alabama, United States
Emergency Administration of EPI-743 to a Single Patient With Leber's Hereditary Optic Neuropathy [LHON]
- Conditions
- Leber's Hereditary Optic Neuropathy
- First Posted Date
- 2014-11-25
- Last Posted Date
- 2014-11-25
- Lead Sponsor
- Edison Pharmaceuticals Inc
- Registration Number
- NCT02300753
- Locations
- 🇺🇸
Doheny Eye Institute / UCLA, Los Angeles, California, United States
Protective Effects of EPI-743 on Noise-Induced Hearing Loss
- First Posted Date
- 2014-10-07
- Last Posted Date
- 2020-11-18
- Lead Sponsor
- Edison Pharmaceuticals Inc
- Target Recruit Count
- 77
- Registration Number
- NCT02257983
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
An Exploratory Open Label Study of EPI-743 (Vincerinone TM) in Children With Autism Spectrum Disorder
- First Posted Date
- 2014-08-27
- Last Posted Date
- 2022-01-21
- Lead Sponsor
- Edison Pharmaceuticals Inc
- Registration Number
- NCT02226458
Phase 2 Study of EPI-743 in Children With Pearson Syndrome
- First Posted Date
- 2014-04-04
- Last Posted Date
- 2020-11-18
- Lead Sponsor
- Edison Pharmaceuticals Inc
- Target Recruit Count
- 2
- Registration Number
- NCT02104336
- Locations
- 🇺🇸
Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸Children's Hospital of Orange County, Orange, California, United States
🇺🇸Baylor College of Medicine, Houston, Texas, United States
Phase 2 Study of EPI-743 for Treatment of Rett Syndrome
- First Posted Date
- 2013-04-02
- Last Posted Date
- 2018-07-26
- Lead Sponsor
- Edison Pharmaceuticals Inc
- Target Recruit Count
- 24
- Registration Number
- NCT01822249
- Locations
- 🇮🇹
University of Siena, Siena, Italy
© Copyright 2025. All Rights Reserved by MedPath